GSK: Future competitor or buyer? From what I've seen on the interwebs, looks like only a couple of other companies are in the BET inhibitor arena. One is Constellation Pharmaceuticals (https://www.constellationpharma.com/) and the other is GlaxoSmithKline.
GSK published on a screen for BET inhibitors to affect apoAI in 2011 (https://www.ncbi.nlm.nih.gov/pubmed/21568322), and in this page from their website discuss this journey that started in 2004 (https://www.gsk.com/explore-gsk/how-we-do-r-and-d/epigenetics---turn-ons-and-turn-offs.html).
So for all you RVX long timers out there, when did RVX first announce that they discovered the RVX-208 effect on apoAI?
Do you think it is more likely that GSK might want to buy out RVX to avoid competition, or do you think it is more likely that another big pharma company would want to buy RVX to compete with or have the edge on GSK?